ACE-Inhibitors, β-Blockers, Spironolactone: Do We Need Many More Drugs to Treat Chronic Heart Failure?

[1]  D. Mann,et al.  Contemporary Medical Options for Treating Patients With Heart Failure , 2002, Circulation.

[2]  R. McKelvie,et al.  Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. , 2002, Journal of the American College of Cardiology.

[3]  J. Cohn,et al.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.

[4]  S Capewell,et al.  More ‘malignant’ than cancer? Five‐year survival following a first admission for heart failure , 2001, European journal of heart failure.

[5]  M. Packer.  Current role of beta-adrenergic blockers in the management of chronic heart failure. , 2001, The American journal of medicine.

[6]  J D Horowitz.  Home-based intervention: the next step in treatment of chronic heart failure? , 2000, European heart journal.

[7]  T. LeJemtel,et al.  Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. , 2000, The New England journal of medicine.

[8]  C. Frampton,et al.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.

[9]  A. Coats.  Heart Failure 99 -- the MOXCON story. , 1999, International journal of cardiology.

[10]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[11]  L. Stevenson.  Inotropic therapy for heart failure. , 1998, The New England journal of medicine.

[12]  J. Soler‐Soler,et al.  Should we still prescribe digoxin in mild-to-moderate heart failure? Is quality of life the issue rather than quantity? , 1998, European heart journal.

[13]  A. Michalsen,et al.  Preventable causative factors leading to hospital admission with decompensated heart failure , 1998, Heart.

[14]  P. Poole‐Wilson,et al.  Successes and failures of current treatment of heart failure , 1998, The Lancet.

[15]  W. Colucci,et al.  New targets for heart-failure therapy: endothelin, inflammatory cytokines, and oxidative stress , 1998, The Lancet.

[16]  W. Abraham,et al.  Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. , 1998, Journal of the American College of Cardiology.

[17]  S. Yusuf,et al.  Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .

[18]  J. Hampton.  Results of clinical trials with diuretics in heart failure. , 1994, British heart journal.

[19]  M. Packer.  The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. , 1992, Journal of the American College of Cardiology.